Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

Cannot have received: radiation therapy

Received prior radiotherapy within 4 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities.

Cannot have received: systemic anticancer therapy

Exception: except for prophylactic intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea

Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention (except for prophylactic intrathecal chemotherapy and/or cytoreductive therapy with steroids/hydroxyurea).

Cannot have received: investigational agent

Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.